1 Lysophosphatidic acid (LPA) has been widely studied as a naturally occurring and multifunctional phospholipid messenger in diverse tissue and cell types and shown to inhibit adenylyl cyclase (AC) by a G protein-mediated mechanism. 2 In type II AC-expressing mouse RAW 264.7 macrophages, we showed that LPA at 3 ± 50 mM increased cyclic AMP formation in a concentration-dependent manner, the eect being additive with that of forskolin or cholera toxin, and synergistic with that of prostaglandin E 1 (PGE 1 ) or isoproterenol.
Introduction
Lysophosphatidic acid (LPA) is a naturally occurring and multifunctional phospholipid messenger in several cell types (reviews see Moolenaar, 1995; Moolenaar et al., 1997) and can elicit a variety of cellular responses, including platelet aggregation, smooth muscle contraction, alterations in neuronal cell morphology, DNA synthesis and proliferation in dierent cell types. It is released from activated platelets or injured cells and is thought to be responsible for much of the cell growth and adhesion promoting activity in serum (Durieux & Lynch, 1993; Moolenaar, 1995) . LPA elicits its biological responses through a receptor coupled to heterotrimeric G proteins. Radioligand binding studies have shown the presence of speci®c LPA binding sites to a membrane protein with apparent molecular mass of 38 ± 40 kDa in various LPAresponsive cell types (van der Bend et al., 1992) . Recent work has also identi®ed three cDNA encoding functional LPA receptors that trigger dierent signalling pathways (Guo et al., 1996; Hecht et al., 1996; An et al., 1997) .
At least four G protein-mediated signalling pathways have been identi®ed in the action of LPA (review see Moolenaar, 1995; Goetzl & An, 1998) . These are (i) stimulation of phospholipase C (PLC) via Gaq/11 and bg dimers, (ii) inhibition of adenylyl cyclase (AC) via Gai, (iii) activation of Ras and the downstream Raf/MAP kinase pathway via bg dimers, and (iv) activation of Rho-dependent signalling elements via G12/13 and leading to the cytoskeleton-dependent functions as well as activation of phospholipase D (PLD) and phosphoinositide 3-kinase. Of these pathways, inhibition of AC and stimulation of Ras signalling are sensitive to pertussis toxin (PTX).
Cyclic AMP is well established as an important second messenger regulating a wide variety of cellular functions. Modulation of cyclic AMP levels is of particular signi®cance in the regulation of macrophage functions, including cytokine synthesis, phagocytosis, adhesiveness, and NO generation (Ventura et al, 1990; Mullet et al., 1997) . Besides the inhibition of AC observed in PC12 cells (Tigyi et al., 1996a) and ®broblasts (Carr et al., 1994) , LPA was found to be responsible for the serum-induced sensitization of cyclic AMP accumulation (Kreps et al., 1993; Nogami et al., 1995) . Divergent mechanisms appear to exist for the sensitization eect on AC activity. The results in airway smooth muscle cells suggested that the bg subunits generated from LPA-activated receptors, which are coupled to both the PTX-sensitive Gi protein and PTX-insensitive Gq protein, are responsible for the enhancement. In addition, protein kinase C (PKC) activation resulting from Gq-triggered phosphoinositide (PI) turnover also leads to the potentiation of AC (Nogami et al., 1995) . The conditionally regulatory role of bg subunit on AC activity has also been demonstrated (Weng et al., 1996; Ahmed & Heppel, 1997) . Apart from these studies, no detailed clari®cation on the signalling mechanism for LPA potentiation in the cyclic AMP system has been obtained.
As understanding of the cyclic AMP pathways is crucial to understanding the regulation of macrophage activation, we investigated here the intracellular signal transduction mechanism of LPA involved in the regulation of cyclic AMP synthesis in murine RAW 264.7 macrophages. The current investigation was undertaken to accomplish the following goals: (1) to evaluate the eect of LPA on cyclic AMP synthesis; (2) to examine the role of PKC on LPA modulation of cyclic AMP synthesis; (3) to identify the PKC isoforms involved in LPAinduced signalling; (4) to examine the changes in cytoskeleton arrangement during the LPA response. We report that LPA is able itself to activate AC, and, in combination with the Gscoupled receptor agonists, prostaglandin E 1 (PGE 1 ) and isoproterenol, can markedly increase cyclic AMP synthesis. This potentiation eect of LPA is primarily due to the activation of atypical PKCs which leads to the stimulation of type II AC.
Methods

Materials
Dulbecco's modi®ed Eagle's medium (DMEM), foetal bovine serum, penicillin and streptomycin were obtained from Gibco BRL (Grand Island, NY, U.S.A.). [
3 H] cyclic AMP assay system, horseradish peroxidase-coupled antimouse and anti-rabbit antibodies, and the enhanced chemiluminescence detection agent were purchased from Amersham International (Arlington Heights, II, U.S.A.). Ro 31-8220 and Go 6976 were purchased from Calbiochem (La Jolla, CA, U.S.A.). Mouse monoclonal antibodies speci®c for PKC a, d, e, l, m and z were purchased from Transduction Laboratories (Lexington, KY, U.S.A.), and rabbit polyclonal antibodies speci®c for PKC bI and bII were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). e-Peptide and z-PKC pseudosubstrate peptide were synthesized by the ABI Peptide Synthesizer. [g-32 P]-ATP was from NEN-Du Pont (Boston, MA, U.S.A.). All materials for SDS ± PAGE and Bio-Rad protein assay were obtained from Bio-Rad Laboratories (Hercules, CA, U.S.A.). Other chemicals were obtained from Sigma (St. Louis, MO, U.S.A.).
Cell culture
Mouse RAW 264.7 macrophages, obtained from the American Type Culture Collection (Bethesda, MD, U.S.A.), were cultured in DMEM /10% foetal bovine serum /100 u ml 71 penicillin and 100 mg ml 71 streptomycin at 378C in a humidi®ed atmosphere of 95% air/5% CO 2 as previously described (Lin & Chen, 1998) .
Measurement of cyclic AMP levels
Intracellular cyclic AMP accumulation was assayed as previously reported (Lin & Chen, 1998) . Brie¯y, con¯uent cells on 35-mm culture plates were washed with physiological saline solution (PSS, composition in mM: NaCl 118, KCl 4.7, CaCl 2 1.8, MgCl 2 1.2, KH 2 PO 4 1.2, glucose 11 and HEPES 20, pH 7.4) and incubated in the presence of 500 mM 3-isobutylmethylxanthine (IBMX) for 20 min at 378C. The reaction was started by addition of the test reagents and continued for 10 min at 378C; it was then terminated by aspirating the reaction mixture and immediately adding 0.1 N HCl. The cells were scraped o and the suspension centrifuged. The supernatant was neutralized and assayed of cyclic AMP levels with the [ 3 H] cyclic AMP assay kit. Cell pellets were assayed for protein content using the Bradford (1976) method and bovine serum albumin as the standard and the cyclic AMP level expressed in pmol mg 71 protein.
Immunoblotting analysis
The cells were placed on ice, rinsed with PBS, resuspended in homogenization buer (in mM): Tris-HCl 20, EGTA 0.5, EDTA 2, DTT 2, p-methylsulphonyl¯uoride 0.5 and 10 mg ml 71 leupeptin, pH 7.5) and sonicated. The protein content of the sonicate was assayed by the Bradford method. Equal amounts of cell lysate protein (80 mg) were separated by 9% polyacrylamide gel electrophoresis in the presence of 0.1% sodium dodecyl sulphate (SDS ± PAGE) and the proteins electrotransferred to nitrocellulose membranes (Amersham ECL grade). The blots were then blocked with TBST buer (Tris-HCl 100 mM, NaCl 150 mM, Tween 20 0.1%, pH 7.5) containing 0.5% nonfat dry milk powder for 12 h at 48C, washed with TBST buer, and incubated with PKC isoformspeci®c primary antibody for 1.5 h. After buer washing, the blots were then incubated with horseradish peroxidaseconjugated anti-mouse or anti-rabbit antibody for 1 h. After an extensive wash, the blots were processed for visualization using the enhanced chemi-luminescence system according to the manufacturer's recommendations (Amersham), and then exposed to Kodak XAR-5 ®lm to obtain the¯uorographic images.
Assessment of atypical PKC activity
Activation of atypical PKC was assessed in situ as previously described (Wooten et al., 1996) . Brie¯y, RAW 264.7 cells were harvested in PSS and 5610 5 cells/each reaction treated with a given stimulus, followed by rapid centrifugation. The supernatant was rapidly removed by aspiration and cell pellets resuspended in 50 ml of permeabilization buer (NaCl 137 mM, KCl 5.4 mM, sodium phosphate 0.3 mM, potassium phosphate 0.4 mM glucose 1 mg ml
71
, HEPES 20 mM, pH 7.2, digitonin 10 mM, MgCl 2 10 mM and b-glycerophosphate 25 mM) in the absence or presence of 150 mM zpseudosubstrate peptide (PKC z sequence 113 ± 129; SIYRR-GARRWRKLYRAN). The reactions were initiated by addition of a mixture consisting of 150 mM e-peptide (PKC e sequence 149 ± 164, pseudosubstrate site in PKCe with Ala 159 substituted by Ser, ERMRPRKRQGSVRRRV) and 100 mM [g-32 P]-ATP. After 10 min incubation at 378C, the kinase reactions were terminated by addition of 30 ml 1% H 3 PO 4 and the reaction mixture processed as described previously (Wooten et al., 1996) . Changes in the activity of atypical PKC were calculated as the dierence in phosphotransferase activity in the presence or absence of z-PKC pseudosubstrate peptide.
Measurement of [Ca 2+ ]i
Cells grown on glass slides were loaded with 3 mM fura-II/AM and pluronic F-127 (0.02% v v 71 ) in DMEM at 378C for 45 min. The¯uorescence was monitored on a PTI M-series spectro¯uorometer using dual excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. The [Ca 2+ ]i was calculated from the ratio of the¯uorescence at the two excitation wavelengths, using a K d value of 224 nM for the fura-II/Ca 2+ equilibrium.
Statistical analysis
Each experiment was performed in duplicate, and the data represent the mean+s.e.mean of several independent experiments. P50.05 was considered signi®cant for evaluation of the data using Student's t-test. The n values represent the number of independent experiments. The error bar was omitted when it fell within the symbol representing the mean value.
Results
Increase in basal and stimuli-induced cyclic AMP accumulation by LPA
The intracellular cyclic AMP level accumulating within 10 min in the presence of the phosphodiesterase inhibitor, IBMX, was assayed. As shown in Figure 1 , LPA concentration-dependently increased cyclic AMP formation within 3 ± 50 mM.
At the highest concentration we tested (50 mM), LPA increase in cyclic AMP did not reach the plateau eect. The increase in cyclic AMP is LPA-speci®c, as the related phospholipids, phosphatidic acid (30 mM) and lysophosphatidylcholine (3 mg ml 71 ) did not stimulate cyclic AMP formation, which were respectively of 16+4 (n=3) In combination with forskolin (10 mM), a direct activator of AC that increased the intracellular cyclic AMP levels from 10+3 to 52+6 (n=15) pmol mg 71 protein, the LPA-induced cyclic AMP response (3,10 and 30 mM) was essentially additive with that of forskolin ( Figure 2a ). Two Gs-coupled receptor agonists, PGE 1 and isoproterenol, at 1 mM, respectively stimulated cyclic AMP formation to 292+40 (n=15) and 185+10 (n=12) pmol mg 71 protein; in the presence of LPA (1 ± 30 mM), these agonist-induced cyclic AMP responses were potentiated (Figure 2b ,c).
Interaction with G protein-acting toxins
Since the LPA receptors have been shown to be members of the G protein-coupling receptors (Moolenaar, 1995; Moolenaar et al., 1997) , we explored the possible involvement of Gs and Gi/ Go proteins in LPA-mediated cyclic AMP increase seen in macrophages. In cells pretreated for 24 h with 100 ng ml 71 PTX, which causes ADP-ribosylation and uncoupling of Gi/ Go function, the potentiation eect of LPA on the PGE 1 response was unchanged (data not shown).
Cholera toxin treatment itself (500 ng ml 71 for 150 min) increased the basal cyclic AMP to 320+60 pmol mg 71 protein (n=4) and also potentiated the production of cyclic AMP induced by PGE 1 (Figure 3) ; the cyclic AMP increase on coaddition of cholera toxin and LPA (30 mM) showed an additive eect. When cells were treated with all three stimuli, cholera toxin, PGE 1 and LPA, a marked potentiation of cyclic AMP formation, about 4 fold greater than the co-stimulated response by PGE 1 and LPA, was seen ( Figure 3 ).
Cytoskeleton-unrelated mechanism of LPA response
Previous studies have demonstrated the Rho-dependent eect of LPA on stress ®bre formation in ®broblasts (Ridley & Hall, 1992; Malcolm et al., 1996) . In order to study the possible involvement of cytoskeletal rearrangement in the LPA-induced AC potentiation, we tested the eect of LPA on stress ®bre formation and also explored the eect of two cytoskeletal inhibitors, colchicine (a microtubule disrupter) and cytochalasin B (an actin ®lament disrupter), which have also been shown to increase AC activity in macrophages (Grunspan-Swirsky & Pick, 1978) . Using FITC-phalloidin to detect actin, actin ®laments were seen in the ®lopodium and the lamellipodium of the ventral and dorsal aspects of serum-cultured RAW 264.7 macrophages ( Figure 4a,b) ; however, no stress ®bres were seen in the cytoplasm. In serum-deprived RAW 264.7 cells, the actin ®laments were present in the ®lopodium and lamellipodium regardless of the presence or absence of LPA (50 mM) (Figure 4c ± f) and LPA did not induce stress ®bre formation in these cells. These results indicated that, in contrast to its eect in ®broblasts (Ridley & Hall, 1992) and C 6 glioma cells (our unpublished data), LPA did not elicit stress ®bre formation. In parallel, the eect of serum deprivation on LPA-induced cyclic AMP potentiation was tested, since LPA has been suggested to be responsible for the serum-induced AC activation (Kreps et al., 1993; Nogami et al., 1995) ; neither the cyclic AMP response of PGE 1 (1 mM) nor the potentiation eect of LPA (1 ± 30 mM) was aected by serum-deprivation for 4 h (data not shown). Figure 5 shows that colchicine (10 mM) and cytochalasin B (10 mg ml 71 ) respectively potentiate PGE 1 -induced cyclic AMP formation by 4.2 or 2.5 fold within 1 h treatment, although neither drug itself increased the basal cyclic AMP Figure 1 Concentration-dependent eect of LPA on cyclic AMP accumulation in RAW 264.7 macrophages. Cells incubated in PSS containing 500 mM IBMX were treated with vehicle (basal) or LPA at the indicated concentration for 10 min, then the intracellular cyclic AMP levels were measured. The values are the mean+s.e.mean of at least three independent experiments. level in the absence of Gs-mediated AC activation (data not shown). The potentiation eects of colchicine and cytochalasin B were additive with that of LPA (10 mM). In addition, the eect of colchicine, but not those of cytochalasin B nor LPA, was sensitive to pretreatment with taxol (20 mM, a microtubule stabilizer) (Figure 5 ), con®rming that the action of colchicine is dependent on microtubule disruption. 
81+8 pmol mg
71 (n=3) in normal PSS), but also potentiated the PGE 1 response to a similar extent (Figure 7) .
To assess the action on PI turnover, we measured [
3 H]-myoinositol prelabelled cells, as previously described (Lin & Chen, 1997) . When assayed in normal PSS containing 10 mM LiCl to selectively inhibit inositol monophosphatase, no signi®cant increase in [ 3 H]-IP accumulation was seen following treatment with concentrations of LPA up to 50 mM (data not shown).
Involvement of PKC in LPA-induced cyclic AMP synthesis
To explore the involvement of PKC on LPA-induced AC activation, the eects of PKC inhibitors and a PKC activator were studied. As shown in Figure 8a , the PKC inhibitors, staurosporine and Ro 31-8220, but not Go 6976, inhibited the LPA (50 mM)-induced cyclic AMP increase. The LPA response was decreased to 38+6% (n=3) and 17+3% (n=4) by 1 mM staurosporine and 10 mM Ro 31-8220, respectively.
The eects of PKC inhibitors on LPA-induced cyclic AMP potentiation of PGE 1 stimulation are shown in Figure 8b . Ro 31-8220 at 10 mM eectively reduced the LPA-induced potentiation of the PGE 1 response from 460+50% (n=3) of control to 128+13% (n=3), and itself moderately attenuated the PGE 1 response alone by 39+7% (n=3). On the other Figure 2 Eects of LPA on forskolin, PGE 1 and isoproterenol stimulation of cyclic AMP production in RAW 264.7 cells. Cells were incubated with various concentrations of LPA plus 10 mM forskolin (a), 1 mM PGE 1 (b) or 1 mM isoproterenol (c) for 10 min, then assayed for cyclic AMP content and protein as described in Methods. The values are the mean+s.e.mean from at least three independent experiments. The values in the parentheses indicate the percentages of potentiation caused by LPA.
hand, Go 6976 at 1 mM slightly increased PGE 1 response by 45+12% (n=3), but failed to signi®cantly attenuate the LPAinduced cyclic AMP potentiation.
To further link the mechanism responsible for the eects of LPA to PKC-mediated signalling, we examined the eects of PKC activation and down-regulation on agonist-induced Figure 3 Interactions between PGE 1 -, LPA-and cholera toxininduced cyclic AMP accumulation. Cells were treated with PGE 1 (1 mM, 10 min) and/or LPA (30 mM, 10 min) following pretreatment with vehicle or cholera toxin (CTX, 500 ng ml 71 . 150 min) as indicated. Note the additive eect of the LPA and CTX responses, and the potentiation eect seen with PGE 1 and CTX in the presence or absence of LPA. The values are the mean+s.e.mean from at least three independent experiments. ]i. Cells labelling with 3 mM fura-2/AM were treated with LPA (1, 10 or 30 mM), and the [Ca 2+ ]i was determined as described in Methods.
induced AC activation. Phorbol 12-myristate-13 acetate (PMA), an activator of classical and novel types of PKC isoforms, can mimic the potentiation eect of LPA. As shown in Figure 9a , pretreatment with 1 mM PMA for 20 min did not aect the basal cyclic AMP level, but increased the PGE 1 response to 211+21% (n=4). The potentiating eects of PMA and LPA, at their respective concentrations for maximal eect, were non-additive. These results, together with those from the PKC inhibitor studies, indicate that PKC activation plays a major role in the action of LPA.
Further studies in cells pre-treated with 1 mM PMA for 24 h showed that the LPA-induced increase in basal cyclic AMP levels ( Figure 9b ) and the potentiation of PGE 1 (Figure 9a ) response were not altered compared with controls, suggesting that the PKC isoform(s) involved in LPA signalling belongs to the PMA-non-down-regulated types. Our previous report has already shown that 24 h pretreatment of RAW 264.7 cells with PMA can inhibit the subsequent eect of PMA in potentiating cyclic AMP response (Lin & Chen, 1998) . To investigate the possible PKC isoform(s) involved in LPA-induced AC activation, down-regulation was performed. Eight PKC isoforms (a, bI, bII, d, e, m, l and z) were identi®ed in RAW 264.7 macrophages by immunoblot analysis; after treatment with 1 mM PMA for 24 h, PKCa, bI, bII and d were downregulated by 95+3%, 85+7%, 96+3% and 80+4%, respectively (n=3), while PKCe, m, l and z were not signi®cantly aected (Figure 10 ).
LPA induced atypical PKC activation
Previous studies have established an in situ kinase assay system for the speci®c detection of the kinase activity of atypical PKC isoforms using PKCe peptide (sequence 149 ± 164) as a substrate and PKCz pseudosubstrate peptide (sequence 113 ± 129) as an inhibitor (Wooten et al., 1996) . As shown in Figure 11a , LPA (50 mM) markedly increased atypical PKC activity at 4 and 7 min after treatment; its concentration-dependent eect is shown in Figure 11b . At concentrations higher than 10 mM, LPA can caused a signi®cant increase in atypical PKC activity, the eect being reached about 5.5 fold at 30 mM.
Discussion
Previous studies have demonstrated several underlying mechanisms involved in the LPA eect on the regulation of cyclic AMP formation. Coupling to Gi-mediated AC inhibiton is one of the signalling pathways for LPA receptors, as seen in Swiss 3T3 mouse ®broblasts (van Corven et al., 1989) and PC12 pheochromocytoma cells (Tigyi et al., 1996a) . In human airway smooth muscle cells, although LPA itself does not aect basal cyclic AMP levels, LPA receptors, coupling to Gi proteins, as well as to Gq proteins, can modulate AC activity by three dierent mechanisms (Nogami et al., 1995) . Firstly, activation of Gia results in the inhibition of forskolin-induced cyclic AMP formation. Secondly, the Gq-triggered PI turnover and PKC activation lead to the potentiation of isoproterenolstimulated type II AC activity. Thirdly, released bg subunits, derived from either Gi or Gq protein, also participate in the potentiation of AC II activity. In human foreskin ®broblasts, LPA elicits opposite eects on cyclic AMP regulation, depending on the stimulation agent used. In contrast to the PTX-sensitive inhibition of AC stimulated by isoproterenol, PGE 2 , cholera toxin and forskolin, LPA enhances ATP-or adenosine-induced cyclic AMP formation; this eect is dependent on the released bg subunits (Ahmed & Heppel, 1997) . Homan et al. (1996) reported that in glial cells, the sensitizing eect of LPA on b-adrenergic agonist-induced Figure 9 Eect of PMA treatment on PGE 1 -and LPA-induced cyclic AMP accumulation. Cells were treated with 1 mM PMA for 20 min or 24 h prior to the addition of PGE 1 (1 mM) and/or LPA (30 mM) for 10 min, as indicated. The values are the mean+s.e.mean from ®ve or six independent experiments. *P50.05 as compared with the control PGE 1 response without PMA pretreatment. **Nonadditivity between LPA-and PMA-induced cyclic AMP accumulation. Figure 11 Eect of LPA on atypical PKC activity. (a) Time-dependent increase in atypical PKC activity following treatment with LPA. RAW 264.7 cells were treated with 50 mM LPA for 0 ± 7 min as indicated. At the end of the stimulation period, the cells were assayed in situ for atypical PKC activity. (b) Concentration-dependent stimulation of atypical PKC activity by LPA. Cells were treated as indicated with 1 ± 50 mM of LPA for 7 min followed by the in situ assay of atypical PKC. The results are expressed as the mean+s.e.mean from three independent experiments. *P50.05 as compared with the control activity. cyclic AMP formation is completely inhibited by PTX, suggesting the involvement of PTX-sensitive G proteins in the LPA eects. All this information implies the multiplicity and cell-type dependency of the LPA-mediated regulation of AC activity. Because of this complexity, the aim of the present study was to explore the underlying mechanism responsible for LPA modulation of the cyclic AMP system in macrophages. We have previously shown that RAW 264.7 macrophages express type II AC, which is a PKC-sensitive AC isoform (Lin & Chen, 1998) . Interestingly, here we demonstrated that LPA can not only activate AC in RAW 264.7 macrophages by itself, but also potentiate agonist-stimulated AC activity via a novel pathway, which requires atypical PKC activation and is independent of PTX-sensitive pathways, PI turnover or a [Ca 2+ ]i increase. The PTX-insensitivity further rules out the involvement of Gi/Go coupling to LPA potentiation of cyclic AMP formation in RAW 264.7 cells.
The modulation of cyclic AMP responses by LPA appeared to occur at the level of AC, and not elsewhere in the cyclic AMP cascade. Exposure of mouse RAW 264.7 macrophages to LPA synergistically increased the stimulation of cyclic AMP levels by Gs-coupled receptor agonists, PGE 1 and isoproterenol. Moreover, LPA treatment also additively increased the cyclic AMP stimulation by distinct mechanisms, such as those involving cholera toxin (an activator acting on Gsa subunit), forskolin (a direct activator of AC), colchicine and cytochalasin B (disrupters of cytoskeleton). Thus, the eect of LPA on AC system might act on the postreceptor level and involve the cyclase itself. As mentioned above, although most, but not all, of the eects of LPA in other cells are sensitive to PTX inhibition, the ineectiveness of PTX on LPA-induced cyclic AMP potentiation rules out the possibility that the eects of LPA in RAW 264.7 cells are mediated via bg subunits released from either Gi or Go proteins. Moreover, the failure of LPA to trigger PI turnover also excludes the participation of Gqderived bg subunits in this potentiation event.
Several pieces of evidence led to the conclusion that the AC stimulation and potentiation eects of LPA are dependent on atypical PKC activation. Firstly, the eect of LPA was blocked by non-selective inhibitors of PKC Ro 31-8220 and staurosporine, while Go 6976, a selective inhibitor of classic PKCa, b and g (Martiny- Baron et al., 1993) , failed to aect it. Secondly, the LPA eect was mimicked by the PKC activator, PMA, and their eects were non-additive. Thirdly, long-term pretreatment with PMA failed to aect the LPA response, suggesting that PKC isoforms resistant to PMA downregulation were involved. Fourthly, immunoblot analysis of RAW 264.7 cells using antibodies speci®c for dierent PKC isozymes revealed the presence of PKC a, bI, bII, d, e, m, l and z in these cells, of these only PKC a, bI, bII and d, were downregulated by 24 h PMA treatment. Fifthly, direct measurement of atypical PKC activity revealed a marked increase on treatment with LPA. Taken together, these data suggest that dierent PKC isoforms are responsible for PMA-or LPAmediated AC activation in RAW 264.7 macrophages. The activation of atypical PKC isoforms is involved in the stimulation of AC by LPA, whereas, as we recently reported in the same cell system, PMA utilizes PKC e and/or m to upregulate AC activity (Lin & Chen, 1998) . Indeed, the type II isozyme of AC able to be stimulated and/or sensitized by PKC has been extensively characterized (Jacobowitz & Iyengar, 1994; Zimmermann & Taussig, 1996) . With regard to the mechanism involved in the activation of atypical PKC by LPA, we ruled out the involvement of diacylglycerol based on the evidence that atypical PKCs are not activated by diacylglycerol (Nishizuka, 1995) . We now plan to carry out further experiments in order to better understand the link between LPA receptors, if it exists in macrophages, and atypical PKC activation. Naturally, a possible direct interaction between LPA and atypical PKC must be considered, since previous in vitro studies have shown direct activation of PKCa and PKCz by LPA at quite high concentrations, e.g. 214 mM (Limatola et al., 1994; Sando & Chertihin, 1996) .
The results from the present study suggest that a cytosketetal change is not likely to be the mechanism involved in LPA-induced cyclic AMP potentiation, although LPA does have cytosketetal eects in certain cell types. For example, it can induce the rapid formation of actin stress ®bres and the assembly of focal adhesion in serum-starved Swiss 3T3 cells (Ridley & Hall, 1992) . These cytoskeletal eects might also result in the dramatic shape changes seen in PC12 cells (Tigyi et al., 1996b) and neuroblastoma cells (Jalink et al., 1993) . Cytoskeletal structures, such as microtubules and micro®la-ments, have been implicated in the regulation of AC activity in response to hormones in a variety of cell systems (Jasper et al., 1995) , and this observation prompted us to investigate the eects of colchicine and cytochalasin B in LPA-mediated cyclic AMP potentiation. These agents are known to disrupt microtubules and micro®laments respectively, and can enhance agonist-stimulated cyclic AMP accumulation. In the present study, we ruled out any involvement of cytoskeletal changes in the LPA-induced cyclic AMP eect because of the following reasons. Firstly, in serum-deprived RAW 264.7 cells LPA does not induce stress ®bre formation or a change in actin staining in the ®lopodium and lamellipodium, but still induces cyclic AMP potentiation. Secondly, treatment of RAW 264.7 cells with cytochalasin B, which is an actin ®lament disassembling agent that blocks LPA-induced shape changes in other cell types (Jalink et al., 1993; Inoue et al., 1995) , had no signi®cant eect on LPA-stimulated cyclic AMP accumulation; colchicine also had no eect on the potentiation eect of LPA. In fact, in RAW 264.7 macrophages, the disassembly of both microtubules and micro®laments facilitated agonist-induced cyclic AMP formation, while taxol, a microtubule stabilizer, selectively blocked the action of colchicine. Thus we conclude that the LPA-induced stimulation of AC II in RAW 264.7 macrophages does not involve cytoskeletal changes.
In RAW 264.7 macrophages, as in many other cell types, such as platelets, PC12 cells, and Xenopus oocytes (Watson et al., 1985; Durieux et al., 1992; Dyer et al., 1992) , LPA induced an increase in [Ca 2+ ]i. Since the basal, PGE 1 -and isoproterenol-mediated cyclic AMP levels in RAW 264.7 macrophages are unaected by Ca 2+ elevating agents (thapsigargin and ionomycin) (data not shown), and since a PKC activator did not increase intracellular free Ca 2+ levels, the LPA-induced increase in cyclic AMP could not be due to the increased intracellular Ca
2+
. Further con®rmation came from the fact that the LPA-increased cyclic AMP was still seen, and actually was more pronounced, in the absence of extracellular Ca , and is not relevant to the inositol trisphosphate-mediated [Ca 2+ ]i transient seen with LPA treatment in ®broblasts (van Corven et al., 1989; Jalink et al., 1990) , PC12 cells (Tigyi et al., 1996b) , mesangial cells (Inoue et al., 1995) and hepatocytes (Im et al., 1997) . In RAW 264.7 cells, LPA did not induce PI hydrolysis at concentrations up to 50 mM. It has been shown that, in addition to its ability to mobilize intracellular Ca 2+ by activation of the PI cascade, LPA can also promote Ca 2+ entry across the plasma membrane in rat glomerular mesangial cells (Inoue et al., 1995) . Further studies will be required to elucidate the precise mechanisms whereby Ca 2+ entry is stimulated by LPA and thus diminishes LPA-increased cyclic AMP formation in RAW 264.7 cells. In this context, by using RT ± PCR, we have ruled out the presence of Ca 2+ -inhibited ACs (types V and VI) in RAW 264.7 cells (data not shown).
As already mentioned, since LPA elicits a wide range of biological responses via its cellular G protein coupled receptors, several lines of evidence suggest that the diverse eects of LPA are mediated by multiple subtypes of LPA receptors with distinct signalling properties and tissue distribution (Durieux & Lynch, 1993; Moolenaar et al., 1997) . Thus, one possible explanation for the opposite eects of LPA on AC activity (for example, inhibition via Gi protein or stimulation via PKC activation) might be due to the celltype speci®c expression of LPA receptor subtypes that activate dierent signalling mechanisms. Up to now at least three mammalian LPA receptors have been cloned (Goetzl & An, 1998) .
In summary, LPA activates atypical PKC in murine RAW 264.7 macrophages, which leads to the stimulation of type II AC and an increase in cyclic AMP formation due to a variety of stimuli. These results demonstrate a novel mechanism of LPA action on the AC system and also show the complexity of LPA-mediated signalling.
